Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) EBITDA: 2023-2025

Historic EBITDA for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Sep 2025 value amounting to -$71.7 million.

  • NewAmsterdam Pharma Co N.V's EBITDA fell 330.66% to -$71.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$220.9 million, marking a year-over-year decrease of 11.03%. This contributed to the annual value of -$241.6 million for FY2024, which is 36.52% down from last year.
  • According to the latest figures from Q3 2025, NewAmsterdam Pharma Co N.V's EBITDA is -$71.7 million, which was down 310.35% from -$17.5 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's EBITDA ranged from a high of -$16.6 million in Q3 2024 and a low of -$93.8 million during Q1 2024.
  • Its 3-year average for EBITDA is -$49.7 million, with a median of -$42.0 million in 2023.
  • In the last 5 years, NewAmsterdam Pharma Co N.V's EBITDA surged by 64.68% in 2024 and then crashed by 330.66% in 2025.
  • Quarterly analysis of 3 years shows NewAmsterdam Pharma Co N.V's EBITDA stood at -$49.5 million in 2023, then crashed by 86.14% to -$92.1 million in 2024, then crashed by 330.66% to -$71.7 million in 2025.
  • Its EBITDA was -$71.7 million in Q3 2025, compared to -$17.5 million in Q2 2025 and -$39.6 million in Q1 2025.